id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-353058-3r6jw5ij	Crotti, Lia	COVID-19 treatments, QT interval and arrhythmic risk: the need for an international Registry on Arrhythmias	2020-05-26		.txt	text/plain	1249	64	48	Indeed, there are already few studies that evaluated QTc and arrhythmic risk in hospitalized COVID-19 patients treated with different QT-prolonging drugs (i.e. hydroxychloroquine/chloroquine, azithromycin, lopinavir/ritonavir). Saleh M et al 10 evaluated 201 COVID-19 patients who during hospitalization received chloroquine/hydroxychloroquine as a monotherapy (61%) or in association with azithromycin (59%). Similar to previous study 9% of patients showed a QTc>500 msec on treatment (3.5% had discontinuation of therapy), but no torsades de pointes or arrhythmic death were reported. To favor the collection of these data in a big number of affected patients and to monitor the occurrence of arrhythmic events in the context of the SARS-CoV2 infection, the International Registry on Arrhythmias in COVID-19 (COVIDAR), was recently established and endorsed by EHRA and ERN GUARD-Heart. The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial	./cache/cord-353058-3r6jw5ij.txt	./txt/cord-353058-3r6jw5ij.txt